{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicj273qnyml2qnd2m3m4hcrmfzcu3cov2w7jk7idnmrsxpz7qbpmy",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mgn72yp63742"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihbvpqeqwlk5hdo5gf3qrdybs4vkaxmi33pfysisb3greel5tuovq"
    },
    "mimeType": "image/jpeg",
    "size": 88220
  },
  "path": "/2026/03/09/biotech-news-setback-for-roche-breast-cancer-drug/?utm_campaign=rss",
  "publishedAt": "2026-03-09T14:16:13.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Business",
    "Pharma",
    "The Readout",
    "biotechnology",
    "drug development",
    "Drug prices",
    "research"
  ],
  "textContent": "Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news",
  "title": "STAT+: A setback for Roche’s breast cancer drug",
  "updatedAt": "2026-03-09T14:16:17.000Z"
}